Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of αvβ6-positive cancers

Bioconjugate Chemistry

Volumn 19, Issue 9, 2008, Pages 1813-1821

  Guan, Huili ^a   McGuire, Michael J ^a   Li, Shunzi ^a   Brown, Kathlynn C ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; CELLS; CONJUGATED POLYMERS; CONTROLLED DRUG DELIVERY; TARGETED DRUG DELIVERY;

ACID POLYMERS; DOXORUBICIN; DOXORUBICIN CONJUGATES; HIGH AFFINITY; INTEGRINS; POLYGLUTAMIC ACIDS; SIDE EFFECT; TETRAMERIC; THERAPEUTIC EFFICACY; TUMOUR CELLS;

PEPTIDES;

ALPHAVBETA6 INTEGRIN; DOXORUBICIN; H2009.1 PEPTIDE; PEPTIDE; POLYGLUTAMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONJUGATE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG NON SMALL CELL CANCER; PEPTIDE SYNTHESIS; PH; PROTEIN STRUCTURE;

EID: 52249083014     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800154f     Document Type: Article

References (55)

1. Oyama, T., Sykes, K. F., Samli, K. N., Minna, J. D., Johnston, S. A., and Brown, K. C. (2003) Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett. 202, 219-230.
2. Zhou, X., Chang, Y., Oyama, T., McGuire, M. J., and Brown, K. C. (2004) Cell-specific delivery of a chemotherapeutic to lung cancer cells. J. Am. Chem. Soc. 129, 15656-15657.
3. 6 as a prognostic biomarker for non-small cell lung cancer. Cancer Res. 67, 5889-5895.
4. Li, C. (2002) Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Delivery Rev. 54, 695-713.
5. Vega, J., Ke, S., Fan, Z., Wallace, S., Charsangavej, C., and Li, C. (2003) Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer. Pharm. Res. 20, 826-832.
6. Zunino, F., Pratesi, A., and Micheloni, A. (1989) Poly(carboxylic acid) polymers as carriers for anthracyclines. J. Controlled Release 10, 65-73.
7. Hoes, C. J. T., Potman, W., van Heeswijk, W. A. R., Mud, J., de Grooth, B. G., Greve, J., and Feijen, J. (1985) Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin. J. Controlled Release 2, 205-213.
8. Li, C., Yu, F. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N., Milas, L., and Wallace, S. (1998) Regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 58, 2404-2409.
9. Li, C., Price, J. E., Milas, L., Hunter, N. R., Ke, S., Yu, D. F., Charnsangavej, C., and Wallace, S. (1999) Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. 5, 891-897.
10. Milas, L., Mason, K. A., Hunter, N., Li, C., and Wallace, S. (2003) Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int. J. Rad. Oncol. Biol. Phys. 55, 707-712.
11. Auzenne, E., Donato, N. J., Li, C., Leroux, E., Price, R. E., Farquhar, D., and Klostergaard, J. (2002) Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res. 8, 573-581.
12. Singer, J. W., de Vries, P., Bhatt, R., Tulinsky, J., Klein, P., Li, C., Milas, L., Lewis, R. A., and Wallace, S. (2000) Conjugation of camptothecins to poly-(L-glutamic acid). Ann. N.Y. Acad. Sci. 922, 136-150.
13. Zou, Y., Wu, Q. P., Tansy, D., Chow, M. C., Hung, C., Charnsangavej, C., and Wallace, S. (2001) Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice. Int. J. Oncol. 18, 331-336.
14. Zou, C., Brewer, M., Cao, X., Zang, R., Lin, J., Deng, Y., and Li, C. (2007) Antitumor activity of 4-(N-hydroxyphenyl) - retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts. Gynecol. Oncol. 107, 441-449.
15. Zhu, G., Cao, X., Chang, J. Y., Milas, L., and Li, C. (2007) Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol. Rep. 18, 645-651.
16. Wen, X., Jackson, E. F., Price, R. E., Kim, E., Wu, Q., Wallace, S., Charsangavej, C., Gelovani, J. G., and Li, C. (2004) Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: A new biodegradable MRI contrast reagent. Bioconjugate Chem. 15, 1408-1415.
17. Melacon, M. P., Wang, Y., Wen, X., Bankson, J. A., Stephens, L. C., Jasser, S., Gelovani, J. G., Myers, J. N., and Li, C. (2007) Development of macromolecular dual-modahty MR-optical imaging for sentinel lymph node mapping. Invest. Rad. 42, 569-578.
18. Jackson, E. F., Esparza-Coss, E., Wen, X., Ng, C. S., Daniel, S. L., Price, R. E., Rivera, B., Charnsangavej, C., Gelovani, J. G., and Li, C. (2007) Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int. J. Rad. Oncol. Biol. Phys. 68, 830-838.
19. Singer, J. W. (2005) Paclitaxel poliglumex (XYOTAX™, CT-2103): A macromolecular taxane. J. Controlled Release 109, 120-126.
20. Nemunaitis, J., Cunningham, C., Senzer, N. S., Gray, M., Oldham, F., Pippen, J., Mennel, R., and Eisenfeld, A. (2005) Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. 23, 671-676.
21. Bonomi, P. (2007) Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 74, 415-422.
22. Jain, R. K. (2001) Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Delivery Rev. 46, 149-168.
23. Phelps, R. M., Johnson, B. E., Ihde, D. C., Gazdar, A. F., Carbone, D. P., Linnoila, P., Matthews, M. J., Bunn, P. A, Carney, D., Minna, J. D., and Mulshine, J. L. (1996) NCI-Navy medical oncology branch cell line database. J. Cell. Biochem. 32-91.
24. Tian, Y., Bromberg, L., Lin, S. N., Hatton, T. A., and Tam, K. C. (2007) Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers. J. Controlled Release 121, 137-145.
25. Bae, Y., Fukushima, S., Harada, A., and Kataoka, K. (2003) Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change. Angew. Chem., Int. Ed. 42, 4640-4643.
26. Ulbrich, K., and Subr, V. (2004) Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Delivery Rev. 56, 1023-1050.
27. Lee, C. C., Gillies, E. R., Fox, M. E., Guillaudeu, S. J., Frechet, J. M. J., Dy, E. E., and Szoka, F. C. (2006) A single dose of doxorubicin- functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. U.S.A. 103, 16649-16654.
28. Hovorka, O., Etrych, T., Subr, V., Strohalm, J., Ulbrich, K., and Rihova, B. (2006) HPMA based macromolecular therapeutics: Internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptide spacer and alos on spacer composition. J Drug Targeting 14, 391-403.
29. Feener, E. P., and King, G. L. (1998) The biochemical and physiological characteristics of receptors. Adv. Drug Delivery Rev. 29, 197-213.
30. Bareford, L., and Swaan, P. (2007) Endocytotic mechanisms for targeted drug delivery. Adv. Drug Delivery Rev. 59, 748-758.
31. Conner, S., and Schmid, S. (2003) Regulated portals of entry into the cell. Nature 422, 37-44.
32. Rodrigues, P. C., Beyer, U., Schumacher, P., Roth, T., Fiebig, H. H., Unger, C., Messori, L., Orioli, P., Paper, D. H., Mulhaupt, R., and Kratz, F. (1999) Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg. Med. Chem. 7, 2517-24.
33. Luo, Y., Bernshaw, N. J., Lu, Z.-R., Kopecek, J., and Prestwich, G. D. (2002) Targeted delivery of doxorubicin by HMPA copolymers-hyaluronan bioconjugates. Pharm. Res. 19, 396-402.
34. Vicent, M. J., and Duncan, R. (2006) Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 24, 39-47.
35. Duncan, R. (2006) Polymer conjugates as anticancer nano-medicines. Nat. Rev. Cancer 688-701.
36. Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Sampson, D. A., Greene, A. K., Corfas, G., and Folkman, J. (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255-261.
37. Kovar, M., Kovar, L., Subr, V., Etrych, T., Ulbrich, K., Mrkvan, T., Loucka, J., and Rihova, B. (2004) HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro. J. Controlled Release 99, 301-314.
38. Kopecek, J., Kopeckova, P., Minko, T., and Lu, Z. (2000) HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61-81.
39. Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., and Trail, P. A. (2002) Cathepsin-B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem. 13, 855-869.
40. Tang, A., Kopeckova, P., and Kopecek, J. (2003) Binding and cytotoxicity of copolymer conjuagtes to lymphocytes mediated by receptor-binding epitopes. Pharm. Res. 20, 360-367.
41. Kovar, M., Mrkvan, T., Strohalm, J., Etrych, T., Ulbrich, K., Stastny, M., and Rihova, B. (2003) HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. J. Controlled Release 92, 315-330.
42. Ulbrich, K., Etrych, T., Chytil, P., Jelinkova, M., and Rihova, B. (2004) Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J. Drug Targeting 12, 477-489.
43. Nan, A., Ghandehari, H., Hebert, C., Siavash, H., Nititakis, N., Reynolds, M., and Sauk, J. J. (2005) Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. J. Drug Targeting 13, 189-197.
44. 6 mRNA in primate epithelial tissues. J. Histochem.Cytochem. 41.
45. 6 Integrin- A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem. 50, 1371-1379.
46. 6 integrin expression in breast carcinoma. Breast Cancer 7, 19-26.
47. Jones, J., Sugiyama, M., Watt, F. M., and Speight, P. M. (1993) Integrin expression in normal, hyperplastic, dysplastic, and malignant oral epithelium. J. Pathol. 169, 235-243.
48. 6 is associated with lymph node metastasis. Pathol. Res. Pract. 199, 57-64.
49. 6 integrin in development, neoplasia, and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108, 2241-2251.
50. 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J. Invest. Derm. 116, 898-904.
51. 6 integrin promotes migration and invasion in squamous carcinoma cells. J. Invest. Derm. 117, 67-73.
52. 6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int. J. Cancer 92, 641-650.
53. 6 integrin induces gelatinase secretion in colon cancer cells. Int. J. Cancer 81, 90-97.
54. 6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon cancer. J. Clin. Invest. 115, 339-347.
55. Kovar, L., Strohalm, J., Chytil, P., Mrkvan, T., Kovar, M., Hovorka, O., Ulbrich, K., and Rihova, B. (2007) The same drug but a different mechanism of action: Comparison of free doxorubicin with two different N-(2-hydroxypropyl) methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. Bioconjugate Chem. 18, 894-902.